biotech · Non small cell lung cancer · oligometastatic hormone sensitive prostate cancer · CERO
CERo Therapeutics
CERO THERAPEUTICS HOLDINGS, INC.
CERo Therapeutics is a biotech organization headquartered in South San Francisco, USA. It trades on NYSE under ticker CERO. Primary therapeutic focus areas include Non small cell lung cancer, oligometastatic hormone sens
Company details
- Status
- Public
- HQ
- 201 Haskins Way, 230, South San Francisco, California 94080, US
- Employees
- 17
- Programs
- 47
- Drugs
- 84
- Patents
- 14
ZOSTER ICO-N-2018-14
Phase 3 · small molecule · Patients, men or women over 18 old, with inoperable vertebral bone metastases who must beneficit treatment with stereotactic radiotherapy
ZOSTER ICO-N-2018-14 for Patients, men or women over 18 old, with inoperable vertebral bone metastases who must beneficit treatment with stereotactic radiotherapy is a Phase 3 program (small_molecule) at CERO THERAPEUTICS HOLDINGS, INC. with 1 ClinicalTrials.gov record(s).
Internal code ZOSTER ICO-N-2018-14
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- CERO THERAPEUTICS HOLDINGS, INC.
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Patients, men or women over 18 old, with inoperable vertebral bone metastases who must beneficit treatment with stereotactic radiotherapy
- Status
- active
- Trials
- 1